Illumina, Inc.

Illumina releases 2022 Corporate Social Responsibility Report

Retrieved on: 
Monday, June 5, 2023
Science, DNA, Education, Corporate social responsibility, Genomics, Dow Jones, Electricity, Medicine, Carbon, CSR, Certification, Organization, Integration, SAN, Illumina, Inc., CDP, STEM, ESG, Diagnosis, Health, Genome, Renewable energy, Management, Illumina

SAN DIEGO, June 5, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report , highlighting the company's commitment to human health, and the progress made by its environmental, social, and governance (ESG) program in 2022.

Key Points: 
  • SAN DIEGO, June 5, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today published its annual Corporate Social Responsibility (CSR) Report , highlighting the company's commitment to human health, and the progress made by its environmental, social, and governance (ESG) program in 2022.
  • In 2022, Illumina confirmed achievement of 100% renewable electricity and carbon neutrality in its direct operations from onsite solar, purchased renewable electricity, renewable energy credits, and carbon offsets.
  • Operate responsibly: In its focus on ethical business practices and operations, Illumina achieved Privacy Information Management ISO 27701 certification in 2022.
  • Illumina will host its third annual virtual ESG Investor Event on June 12; register here to attend .

Illumina's Board of Directors elects two experienced Independent Directors to Board

Retrieved on: 
Friday, June 2, 2023
Illumina, Inc., DNA, Food, Pharmacia, Boston Scientific, Audit committee, Aspen, Davidson College, Goldman Sachs, Bank of America, Procter & Gamble, DePauw University, SAN, Texas Instruments, Corporation, Harvard Business School, CFO, Aspen Institute, Johnson & Johnson, Nursing care plan, Bank, Compensated emancipation, Management, Hologic, Illumina, Economics

SAN DIEGO, June 2, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a series of governance changes consistent with the goal of enhancing long-term shareholder value.

Key Points: 
  • The Board has elected two new independent board members to join the board immediately.
  • The two join a strong, independent board with world-class talent and unique and differentiated skillsets.
  • "Both Steve and Scott collectively bring more than 30 years of experience in healthcare, and the appointments are part of our continual process to attract strong independent directors.
  • He is currently a member of the board of directors of both Berry Global and egnite, as well as a Henry Crown Fellow at the Aspen Institute.

Illumina unveils AI software to predict disease-causing genetic mutations in patients

Retrieved on: 
Thursday, June 1, 2023
DNA, Biobank, UK Biobank, Diabetes, ChatGPT, Genomics, Language, Bangladesh Technical Education Board, Publication, Patient, Primate, Illumina, Inc., SAN, Medicine, Disease, Artificial intelligence, Security (finance), Form 10-K, Health, Bias, AlphaFold, DSM-IV codes, Genome, Medical imaging, Pharmaceutical industry, Vaccine, Science, Illumina, AI

SAN DIEGO, June 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients. The results are published in two papers in the June 2 issue of Science (issue 6648), detailing the training of the algorithm and its application to half a million genomes in the UK Biobank cohort. Two accompanying papers on the primate evolution research that informed the development of PrimateAI-3D also published in the journal today.

Key Points: 
  • SAN DIEGO, June 1, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the new PrimateAI-3D, an artificial intelligence (AI) algorithm that predicts with unprecedented accuracy disease-causing genetic mutations in patients.
  • Two accompanying papers on the primate evolution research that informed the development of PrimateAI-3D also published in the journal today.
  • "It is exciting to see PrimateAI-3D and the latest in AI technology combine with the most advanced DNA sequencing capabilities," said Francis deSouza, chief executive officer of Illumina.
  • PrimateAI-3D will be made broadly available to the genomics community PrimateAI-3D will be made broadly available to the genomics community integrated across Illumina Connected Software.

Real-world study data reveals better outcomes for cancer patients who receive comprehensive genomic testing

Retrieved on: 
Tuesday, May 30, 2023
SEQUOIA, DNA, CGP, Genomics, American Society of Clinical Oncology, Marie Cassidy, NGS, Survival, Cancer, Research, Biomarker, Plasma, Patient, Standard of care, SAN, Illumina, Inc., Annual general meeting, Diagnosis, Health, Society, Allegheny Health Network, Medical imaging, Pharmaceutical industry, Illumina

SAN DIEGO, May 30, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced some of the latest data on the impact of comprehensive genomic profiling (CGP) for oncology patients, which will be presented at the American Society of Clinical Oncology's Annual Meeting June 2–6 in Chicago. In addition to the real-world study data, Illumina, along with study collaborators, will also present on findings that expose gaps in current standard-of-care and unmet needs for cancer patients.

Key Points: 
  • In addition to the real-world study data, Illumina, along with study collaborators, will also present on findings that expose gaps in current standard-of-care and unmet needs for cancer patients.
  • This study showcases the significant impact of implementing CGP testing systematically at the point of diagnosis, underscoring its potential to significantly improve survival rates in advanced stage cancer patients."
  • Illumina will also present two posters illustrating both the gaps in current testing practices and a study indicating that a large percentage of cancer patients who are eligible for biomarker testing are not receiving any genomic testing whatsoever.
  • It found that across tumor types, between 50% and 80% of advanced cancer patients (those eligible for biomarker testing and with clinical practice guidelines recommending testing) do not receive any kind of genomic testing.

Next-Generation Breast Cancer Diagnostic and Screening Global Market to 2032: Growing Scope for Molecular Breast Cancer Diagnosis Techniques in Emerging Countries Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, May 26, 2023
Biotechnology, Health, Oncology, Partnership, Prevalence, NGS, Liquid biopsy, Prognosis, Biomarker, Automation, Patient, MUFG Americas Holdings Corporation, Illumina, Inc., HALO, Labcorp, Omnigenic model, Agilent Technologies, Growth, Diagnosis, Association for Molecular Pathology v. Myriad Genetics, Inc., Center for Urban and Regional Analysis, FDA, Breast cancer, Medical imaging, Vaccine

The global next-generation breast cancer diagnostic and screening market was valued at $3,137.4 million in 2022 and is anticipated to reach $9,880.1 million by 2032, witnessing a CAGR of 12.57% during the forecast period 2023-2032.

Key Points: 
  • The global next-generation breast cancer diagnostic and screening market was valued at $3,137.4 million in 2022 and is anticipated to reach $9,880.1 million by 2032, witnessing a CAGR of 12.57% during the forecast period 2023-2032.
  • The growth in the global next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases globally, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.
  • The next-generation breast cancer diagnostic and screening market is in the developing phase.
  • Technological advancements in the development of next-generation breast cancer diagnostics and the growing scope for molecular breast cancer diagnosis techniques in emerging countries can be some of the major opportunities in the global next-generation breast cancer diagnostic and screening market.

Global NGS Data Storage Market 2023 to 2033: Data Compression Efforts by Companies Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, May 26, 2023
Technology, Data Management, Cloud, Informatics, EWG, Amazon Web Services, QIAGEN, Twist Bioscience, Community Cyberinfrastructure for Advanced Microbial Ecology Research and Analysis, Software, Genomics, National Association of Testing Authorities, NGS, COVID-19, NATA, System, Mass meeting, Microsoft, Research, Whole genome sequencing, Sequence, Laboratory, Google Cloud, Algorithm, Twist, QDI, Microsoft Azure, WGS, Growth, Azure, Region, Rare, National Association, WES, Genome, Illumina, Inc., Video game, Pharmaceutical industry

The global NGS data storage market is projected to reach $6.96 billion by 2033 from $1.13 billion in 2022, growing at a CAGR of 18.02% during the forecast period 2023-2033.

Key Points: 
  • The global NGS data storage market is projected to reach $6.96 billion by 2033 from $1.13 billion in 2022, growing at a CAGR of 18.02% during the forecast period 2023-2033.
  • Several companies have developed NGS informatics solutions to aid healthcare institutions and academic research centers.
  • NGS data is critical to researchers that offer storage solutions that are reliable while being easy to manage.
  • These services offer pay-as-you-go models, which make it easier for researchers to manage costs based on their data storage needs.

Global Functional Genomics Market Report 2023: Sector is Expected to Reach $46.24 Billion by 2033 at a CAGR of 14.04% - ResearchAndMarkets.com

Retrieved on: 
Friday, May 26, 2023
Health, Genetics, Pacific Biosciences, Symphogen, DNA, BIS, Partnership, Workflow, Epigenomics, Research, Thermo Fisher Scientific, Genomics, RNA, Proteomics, Protein, Data analysis, Oxford Nanopore Technologies, Laboratory, Illumina, Inc., Metabolomics, Medicine, Growth, Region, Gene, Disease, Genome, Antibiotics

In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033.

Key Points: 
  • In 2022, the global functional genomics market was valued at $10.57 billion, and it is expected to reach $46.24 billion by 2033, growing at a CAGR of 14.04% during the forecast period 2023-2033.
  • The growth in the global functional genomics market is expected to be driven by its increased applications especially in targeted therapy and precision medicine.
  • Functional genomics is the study of genes and their interactions in different biological processes.
  • According to BIS Research functional genomics products are used in DNA level (epigenomics), RNA level (transcriptomics), protein level (proteomics) or metabolite level (metabolomics).

Illumina increases equitable access to STEM education, reaching over 1 million learners

Retrieved on: 
Tuesday, May 2, 2023
Learning, DNA, Partnership, Discovery, Inc., Social impact, Education, Human, Curriculum, Musical Futures, The Future's So Bright, I Gotta Wear Shades, Genomics, Science, Future, Organization, School, Student, Museum, Illumina, Inc., United Kingdom, STEM, Commercial Operating System, Human Genome Project, Title, Elementary and Secondary Education Act, Tutoring, Tourism, Management, Illumina

SAN DIEGO, May 2, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced outcomes from its annual The Future Is Bright campaign, a monthlong global genomic literacy initiative, in which Illumina employees connect with students by hosting career panels, implementing genomics curricula, and leading hands-on experiments.

Key Points: 
  • The Future Is Bright activities reached 100,000 learners in April and have reached 200,000 since the initiative launched in 2021.
  • Through The Future Is Bright and other Illumina-supported programming aimed at driving equitable access to STEM education , Illumina has reached more than 1.2 million learners in 11 countries worldwide.
  • In 2022, Illumina achieved its 2030 target of 50% employee participation in its Illumina Cares volunteering programs, amounting to 49,827 volunteer hours since 2019.
  • Illumina aims to reach 5 million STEM learners by 2030 globally.

Asia-Pacific and Middle East NGS Market to 2027: Increasing Adoption of NGS in Various Research and Diagnostics Fields Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 27, 2023
Health, Genetics, Prevalence, Face, Abraxis BioScience, NGS, Research, Genomics, High fidelity, WGS, IVD, Growth, FDA, Illumina, Inc., Video game, Agriculture, Illumina

The market is driven by factors such as the increasing adoption of NGS in various research and diagnostics fields, growing prevalence of non-communicable disorders, and advancement in the performance of NGS platforms.

Key Points: 
  • The market is driven by factors such as the increasing adoption of NGS in various research and diagnostics fields, growing prevalence of non-communicable disorders, and advancement in the performance of NGS platforms.
  • The Asia-Pacific and Middle East NGS market is highly consolidated.
  • The opportunity for growth of the Asia-Pacific and Middle East NGS market lies in development of economical and portable technologies.
  • The following are the drivers for the Asia-Pacific and Middle East NGS market:
    The market is expected to face some limitations as well due to the following challenges:

Genomics Market to Reach $94.86 Billion by 2030 at CAGR 16.5%: Grand View Research, Inc.

Retrieved on: 
Wednesday, April 19, 2023
Metagenomics, Survivor, CRISPR, Molecular epidemiology, Chromosome, Therapy, SARS-CoV-2, Genomics, National Centre for Disease Control, University of Cambridge, NGS, IHOP, National Cancer Institute, Pathway analysis, Inherited disorders of trafficking, Research, Genetic Alliance, Infection, OGL, DSM-IV codes, Biomarker, USD, Government, CDC, Whole genome sequencing, Revenue, Nature, SAN, Biomarker discovery, Functional genomics, Cancer, Merck & Co., Rare, Gene, Genetic disorder, Disease, Illumina, Inc., Antibiotics, Vaccine, Epigenomics

SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, April 19, 2023 /PRNewswire/ -- The global genomics market size is expected to reach USD 94.86 billion by 2030, according to a new report by Grand View Research, Inc.
  • The market is expected to register a CAGR of 16.5% in the forecast period owing to the increasing demand for novel therapeutic and research applications in genomics.
  • Read full market research report more latest industry insights, " Genomics Market Size, Share & Trends Analysis Report By Technology & Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery), By Deliverables, End-use, By Region, And Segment Forecasts, 2023 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global genomics market on the basis of application, deliverables, end-use, and region
    Genomics Market - Application & Technology Outlook (Revenue, USD Million, 2018 - 2030)